Table 1.
Patient and treatment characteristics
| Clinical characteristic | Group A, (n=26), N (%) |
Group B, (n=23), N (%) |
Group C, (n=21), N (%) |
P-value |
|---|---|---|---|---|
| Age (years) | ||||
| Median (range) | 57.23 (45–76) | 55.56 (36–72) | 51.43 (33–75) | 0.141 |
| ≤60 | 17 (65.4) | 17 (73.9) | 19 (90.5) | |
| >60 | 9 (34.6) | 6 (26.1) | 2 (9.5) | |
| Gender | ||||
| Male | 16 (61.5) | 15 (65.2) | 14 (66.7) | 0.930 |
| Female | 10 (38.5) | 8 (34.8) | 7 (33.3) | |
| CEA (ng/mL) | ||||
| ≤5.0 | 20 (76.9) | 15 (65.2) | 17 (81.0) | 0.465 |
| >5.0 | 3 (11.5) | 5 (21.7) | 4 (19.0) | |
| Tumor distribution | ||||
| Solitary | 22 (84.6) | 18 (78.3) | 18 (85.7) | 0.787 |
| Multifocal | 4 (15.4) | 5 (21.7) | 3 (14.3) | |
| Tumor size | ||||
| ≤5 cm | 12 (46.2) | 9 (39.1) | 9 (42.9) | 0.884 |
| >5 cm | 14 (53.8) | 14 (60.9) | 12 (57.1) | |
| Mean margin distance (mm) (SD) | 1.37 mm (2.75) | 1.52 mm (1.84) | – | 0.271 |
| Null-margin resection | 14 (53.8) | 9 (39.1) | – | 0.303 |
| Positive lymph node | 4 (15.4) | 6 (26.1) | 3 (14.3) | 0.449 |
| Stage (AJCC, seventh edition) | ||||
| Stage I | 5 (19.2) | 4 (17.4) | 9 (42.9) | 0.276 |
| Stage II | 9 (34.6) | 7 (30.4) | 4 (19.0) | |
| Stage III | 8 (30.8) | 6 (26.1) | 5 (23.8) | |
| Stage IVA | 4 (15.4) | 6 (26.1) | 3 (14.3) | |
| Histological grading (WHO) | ||||
| Well | 2 (7.7) | 0 (0.0) | 1 (4.8) | 0.320 |
| Moderate | 13 (50.0) | 12 (52.2) | 5 (23.8) | |
| Poor | 10 (38.5) | 10 (43.5) | 11 (52.4) | |
| Unclear | 1 (3.8) | 1 (4.3) | 4 (19.0) | |
| Resection type | ||||
| Anatomical resection | 10 (38.5) | 15 (65.2) | 8 (38.1) | 0.106 |
| Nonanatomical resection | 16 (61.5) | 8 (34.8) | 13 (61.9) | |
| Liver capsule invasion | 17 (65.4) | 17 (73.9) | 17 (81) | 0.499 |
| Intraoperative blood transfusion | 4 (15.4) | 7 (30.4) | 1 (4.8) | 0.089 |
| Treatment modalities after recurrence | ||||
| Chemotherapy | 2 (7.7) | 2 (8.7) | 2 (9.5) | 0.484 |
| Radiofrequency ablation or transarterial interventional therapy | 3 (11.5) | 3 (13.0) | 5 (23.8) | |
| Surgery | 0 (0) | 0 (0) | 1 (4.8) | |
| Radiotherapy | 0 (0) | 1 (4.3) | 0 (0) | |
| Othersa | 9 (34.6) | 8 (34.8) | 3 (14.3) |
Notes:
a
Including patients received supportive care or traditional Chinese medicine as palliative treatment. Group A, narrow-margin hepatectomy plus postoperative radiotherapy; Group B, narrow-margin hepatectomy alone; Group C, wide-margin hepatectomy alone.
Abbreviations: CEA, carcinoembryonic antigen; SD, standard deviation; AJCC, American Joint Committee on Cancer; WHO, World Health Organization.